Second-Line Treatment in Patients (pts) with Advanced Extra-Pulmonary Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC): A Systematic Review and Meta-Analysis

被引：0
|
作者：
McNamara, M. G. [1 ]
Frizziero, M. [2 ]
Jacobs, T. [2 ]
Lamarca, A. [2 ]
Hubner, R. [2 ]
Valle, J. W. [1 ]
Amir, E. [3 ]
机构：
[1] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
second-line therapy; neuroendocrine carcinoma; response rate; survival; extra-pulmonary;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J12
引用
收藏
页码：188 / 188
页数：1
相关论文
共 50 条
  • [21] Second-line Agents in Pediatric Patients With Autoimmune Hepatitis: A Systematic Review and Meta-analysis
    Zizzo, Andreanne N.
    Valentino, Pamela L.
    Shah, Prakesh S.
    Kamath, Binita M.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 65 (01): : 6 - 15
  • [22] PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
    Xinxin Zhu
    Qiyue Shanzhou
    Danyang Li
    Xuezhou Pang
    Daiyuan Ma
    BMC Cancer, 21
  • [23] PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
    Zhu, Xinxin
    Shanzhou, Qiyue
    Li, Danyang
    Pang, Xuezhou
    Ma, Daiyuan
    BMC CANCER, 2021, 21 (01)
  • [24] A parametric network meta-analysis of PD-1 inhibitors in second-line treatment for advanced esophageal squamous cell carcinoma
    Pandey, S.
    Sharma, A.
    Singh, B.
    Kaur, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1480 - S1481
  • [25] The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
    McNamara, Mairead Geraldine
    Pearce, Simon
    Swain, Jayne
    Halford, Mollie Anne
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Wadsley, Jonathan
    Morgan, Carys
    Wall, Lucy R.
    Chau, Ian
    Reed, Nick
    Sarker, Debashis
    Margetts, Jane
    Anthoney, Alan
    Oughton, Jamie B.
    Lamarca, Angela
    Hubner, Richard
    Rothwell, Dominic G.
    Valle, Juan W.
    Clipson, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori
    Munoz, Neus
    Sanchez-Delgado, Jordi
    Baylina, Mireia
    Puig, Ignasi
    Lopez-Gongora, Sheila
    Suarez, David
    Calvet, Xavier
    HELICOBACTER, 2018, 23 (03)
  • [27] Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis
    Laukhtina, Ekaterina
    Mori, Keiichiro
    Mostafaei, Hadi
    Merseburger, Axel S.
    Nyirady, Peter
    Moschini, Marco
    Quhal, Fahad
    Schuettfort, Victor M.
    Pradere, Benjamin
    Motlagh, Reza Sari
    Enikeev, Dmitry
    Shariat, Shahrokh F.
    IMMUNOTHERAPY, 2021, 13 (11) : 917 - 930
  • [28] ADVERSE EVENTS OF THE SECOND-LINE TREATMENT STRATEGIES FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Laukhtina, Ekaterina
    Mori, Keiichiro
    Mostafaei, Hadi
    Merseburger, Axel S.
    Nyirady, Peter
    Moschini, Marco
    Quhal, Fahad
    Pradere, Benjamin
    Motlagh, Reza Sari
    Schuettfort, Victor M.
    Enikeev, Dmitry
    Shariat, Shahrokh F.
    JOURNAL OF UROLOGY, 2021, 206 : E768 - E769
  • [29] Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
    Zahra Goudarzi
    Mehrdad Mostafavi
    Mahmood Salesi
    Mojtaba Jafari
    Iman Mirian
    Amir Hashemi Meshkini
    Khosro Keshavarz
    Younes Ghasemi
    Cost Effectiveness and Resource Allocation, 21
  • [30] Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review
    Zhu, Kanghao
    Chen, Hui
    Xu, Congcong
    Chen, Dong
    Jin, Zixian
    Ren, Sijia
    Witharana, Pasan
    Chen, Baofu
    Shen, Jianfei
    JOURNAL OF THORACIC DISEASE, 2023, 15 (03) : 1186 - +
12345